• Home
  • Search
  • Quantitative Diffusion-Weighted MRI of Neuroblastoma
  • Cite Icon4
  • https://doi.org/10.3390/cancers15071940Copy DOI Icon

Quantitative Diffusion-Weighted MRI of Neuroblastoma

  • Mar 23, 2023
  • Cancers
  • Niklas Abele +4 more
Show More
  • Abstract
  • Highlights & Summary
  • PDF
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

Simple SummaryIn this study quantified diffusion weitgthed imaging in MRI was analized in neuroblastoma. We were able to show a significant increase of apparent diffusion coefficient in regressive diseases and a decrease for progressive diseases. This was even true within the first 120 days after the start of therapy.Neuroblastoma is the most common extracranial, malignant, solid tumor found in children. In more than one-third of cases, the tumor is in an advanced stage, with limited resectability. The treatment options include resection, with or without (neo-/) adjuvant therapy, and conservative therapy, the latter even with curative intent. Contrast-enhanced MRI is used for staging and therapy monitoring. Diffusion-weighted imaging (DWI) is often included. DWI allows for a calculation of the apparent diffusion coefficient (ADC) for quantitative assessment. Histological tumor characteristics can be derived from ADC maps. Monitoring the response to treatment is possible using ADC maps, with an increase in ADC values in cases of a response to therapy. Changes in the ADC value precede volume reduction. The usual criteria for determining the response to therapy can therefore be supplemented by ADC values. While these changes have been observed in neuroblastoma, early changes in the ADC value in response to therapy are less well described. In this study, we evaluated whether there is an early change in the ADC values in neuroblastoma under therapy; if this change depends on the form of therapy; and whether this change may serve as a prognostic marker. We retrospectively evaluated neuroblastoma cases treated in our institution between June 2007 and August 2014. The examinations were grouped as ‘prestaging’; ‘intermediate staging’; ‘final staging’; and ‘follow-up’. A classification of “progress”, “stable disease”, or “regress” was made. For the determination of ADC values, regions of interest were drawn along the borders of all tumor manifestations. To calculate ADC changes (∆ADC), the respective MRI of the prestaging was used as a reference point or, in the case of therapies that took place directly after previous therapies, the associated previous staging. In the follow-up examinations, the previous examination was used as a reference point. The ∆ADC were grouped into ∆ADCregress for regressive disease, ∆ADCstable for stable disease, and ∆ADC for progressive disease. In addition, examinations at 60 to 120 days from the baseline were grouped as er∆ADCregress, er∆ADCstable, and er∆ADCprogress. Any differences were tested for significance using the Mann–Whitney test (level of significance: p < 0.05). In total, 34 patients with 40 evaluable tumor manifestations and 121 diffusion-weighted MRI examinations were finally included. Twenty-seven patients had INSS stage IV neuroblastoma, and seven had INSS stage III neuroblastoma. A positive N-Myc expression was found in 11 tumor diseases, and 17 patients tested negative for N-Myc (with six cases having no information). 26 patients were assigned to the high-risk group according to INRG and eight patients to the intermediate-risk group. There was a significant difference in mean ADC values from the high-risk group compared to those from the intermediate-risk group, according to INRG. The differences between the mean ∆ADC values (absolute and percentage) according to the course of the disease were significant: between ∆ADCregress and ∆ADCstable, between ∆ADCprogress and ∆ADCstable, as well as between ∆ADCregress and ∆ADCprogress. The differences between the mean er∆ADC values (absolute and percentage) according to the course of the disease were significant: between er∆ADCregress and er∆ADCstable, as well as between er∆ADCregress and er∆ADCprogress. Forms of therapy, N-Myc status, and risk groups showed no further significant differences in mean ADC values and ∆ADC/er∆ADC. A clear connection between the ADC changes and the response to therapy could be demonstrated. This held true even within the first 120 days after the start of therapy: an increase in the ADC value corresponds to a probable response to therapy, while a decrease predicts progression. Minimal or no changes were seen in cases of stable disease.

Loading PDF

Similar Papers
  • Research Article
  • Citations26

Diffusion-weighted perinatal postmortem magnetic resonance imaging as a marker of postmortem interval.

  • Dec 18, 2014
  • European Radiology
  • Owen J Arthurs +6
  • Research Article
  • Citations1

Pediatric Versus Adult Nasopharyngeal Cancer in Diffusion-Weighted Magnetic Resonance Imaging

  • Jul 03, 2025
  • Cancers
  • Emil Crasnean +12
  • Research Article
  • Citations7

The utility of diffusion-weighted imaging and ADC values in the characterization of mumps orchitis and seminoma.

  • Feb 08, 2021
  • Acta Radiologica
  • Renwei Liu +7
  • Research Article
  • Citations27

In vivo and ex vivo measurements of the mean ADC values of lipid necrotic core and hemorrhage obtained from diffusion weighted imaging in human atherosclerotic plaques

  • Sep 16, 2011
  • Journal of Magnetic Resonance Imaging
  • Seong‐Eun Kim +6
  • Research Article
  • Citations5

Role of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis and Grading of Hepatic Steatosis in Patients With Non-alcoholic Fatty Liver Disease: Comparison With Ultrasonography and Magnetic Resonance Spectroscopy

  • Feb 27, 2021
  • Journal of Clinical and Experimental Hepatology
  • Nikhil Makhija +3
  • Research Article
  • Citations2

Evaluating transcatheter arterial chemoembolization for primary hepatic cancer by magnetic resonance diffusion-weighted imaging

  • Nov 01, 2008
  • Chinese Medical Journal
  • Wei-Jun Fan +4
  • Research Article
  • Citations33

Is there any relationship between adc values of diffusion-weighted imaging and the histopathological prognostic factors of invasive ductal carcinoma?

  • Jan 12, 2018
  • The British Journal of Radiology
  • Hale Aydin +6
  • Research Article
  • Citations6

Accuracy of apparent diffusion coefficients and enhancement ratios on magnetic resonance imaging in differentiating primary cerebral lymphomas from glioblastoma.

  • Jun 12, 2019
  • The Neuroradiology Journal
  • Shayan Sirat Maheen Anwar +6
  • Research Article
  • Citations3

Value of MR diffusion-weighted imaging in diagnosis and outcome prediction for uterine cervical cancer

  • Jan 01, 2014
  • Chinese journal of oncology
  • Xiaohua Wu +7
  • Research Article
  • Citations1

Association of Diffusion Weighted Magnetic Resonance Imaging Profile and Apparent Diffusion Coefficient Value with Brain Tumor’s Histopathology

  • Apr 25, 2020
  • Indian Journal of Forensic Medicine &amp; Toxicology
  • Hartati Rusmi Tri Wilujeng +2
  • PDF
  • Research Article
  • Citations49

Apparent Diffusion Coefficient for Distinguishing Between Malignant and Benign Lesions in the Head and Neck Region: A Systematic Review and Meta-Analysis

  • Jan 08, 2020
  • Frontiers in Oncology
  • Alexey Surov +2
  • Research Article

The Diagnostic Ability of Texture Analysis in MR Imaging for Neurogenic Tumors.

  • Jan 01, 2025
  • The journal of medical investigation : JMI
  • Tomoki Matsushita +6
  • Research Article
  • Citations25

FUNCTIONAL EVALUATION OF HYDRONEPHROSIS BY DIFFUSION-WEIGHTED MR IMAGING. Relationship between apparent diffusion coefficient and split glomerular filtration rate

  • Nov 01, 2000
  • Acta Radiologica
  • S Toyoshima +4
  • Research Article
  • Citations331

ADC Mapping of Benign and Malignant Breast Tumors

  • Jan 01, 2005
  • Magnetic Resonance in Medical Sciences
  • Reiko Woodhams +8
  • Research Article
  • Citations2

Application value of apparent diffusion coefficient in differentiation of brain radiation-injuries and glioma recurrence.

  • Aug 01, 2012
  • Acta Academiae Medicinae Sinicae
  • Yulin Wang +6
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.